Please select the option that best describes you:
Would you offer adjuvant immunotherapy (pembrolizumab) for chromophobe RCC with R1 resection?
Adjuvant IO therapy, radiation therapy, both, or neither?
Answer from: Medical Oncologist at Academic Institution
I have not experienced this situation yet in my own clinical practice but I would not offer adjuvant IO nor adjuvant radiation therapy for this patient.
IO therapy has limited efficacy in this histology. This was shown best in the KEYNOTE-427 (monotherapy pembrolizumab in metastatic nccRCC, M...
Sign in or Register to read more